Screener
Zymeworks ZYME ZW251 — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Zymeworks in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Zymeworks’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001937653-26-000047
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| ZW171 | (458) | 3,322 | 691 | 5,549 |
| ZW191 | 3,127 | 2,764 | 6,158 | 4,470 |
| ZW220 | (152) | 327 | (55) | 2,525 |
| ZW251 | 3,205 | 2,340 | 5,112 | 6,291 |
| Expense for other preclinical and research programs | 4,192 | 6,174 | 11,456 | 12,250 |
| Unallocated research and development expenses: | ||||
| Salaries and benefits and stock based compensation | 10,681 | 12,034 | 25,440 | 24,757 |
| Other research and development expense | 4,659 | 5,987 | 10,285 | 11,440 |
Item 1. Financial Statements
FAQ
- What is Zymeworks's ZW251 — R&D?
- Zymeworks (ZYME) reported ZW251 — R&D of $3.21M in Q2 2026.
- What does ZW251 — R&D mean?
- This metric represents the total investment allocated to the research and development activities specifically associated with the ZW251 product candidate. It captures the resources dedicated to advancing this specific therapeutic asset through its clinical development lifecycle. Monitoring this spend provides insight into the company's strategic prioritization of its pipeline assets.
Ask your AI about Zymeworks's zw251 — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude